ACET | Adicet Bio, Inc. Stock Overview

(Stock Exchange: NASDAQ)

Day's Range	0.9434 - 1.0600
52 Week Range	0.9300 - 3.77
Beta	1.72
Implied Volatility	244.02%
IV Rank	74.06%
Day's Volume	961,781
Average Volume	459,765
Shares Outstanding	82,401,000
Market Cap	79,690,007
Sector	Healthcare
Industry	Biotechnology
IPO Date	2018-01-26

Valuation
Profitability
Growth
Health
P/E Ratio	-0.57
Forward P/E Ratio	N/A
EPS	-1.70
1YR Price Target	N/A
Dividend Yield	N/A
Dividend Per Share	N/A
Dividend ExDate	N/A
Dividend PayDate	N/A
Employees	143
Country	USA
Website	ACET

Adicet Bio, Inc., a biotechnology company, discovers and develops allogeneic gamma delta T cell therapies for cancer and other diseases. The company offers gamma delta T cells engineered with chimeric antigen receptors and T cell receptor-like antibodies to enhance selective tumor targeting, facilitate innate and adaptive anti-tumor immune response, and enhance persistence for durable activity in patients. Its lead product in pipeline includes ADI-001, which is in Phase I clinical study for the treatment of non-Hodgkin's lymphoma. The company also engages in the development of ADI-002, which is undergoing preclinical studies for the treatment of various solid tumors. Adicet Bio, Inc. is based in Boston, Massachusetts.

ACET's peers: EWTX, TALS, CGEM, VOR, TNYA, BCYC, IGMS, GLUE, STOK, AVTE, ACRV, ANEB, AGIO, FIXX, NKTX, PLRX, ALEC, AADI, KROS, ADAP, HOWL, OABI

*Chart delayed

Analyzing fundamentals for ACET we got that it has weak fundamentals where Valuation is considered to be significantly overvalued, Profitability is unacceptably poor, Growth is desperately bad and Health is weak. For more detailed analysis please see ACET Fundamentals page.

Watching at ACET technicals we can see that long-term trend is bearish, the same as bearish middle-term trend, as well as bearish short-term trend. More technicals details can be found on ACET Technicals page.